Thermo Fisher Scientific (TMO) Common Equity (2016 - 2025)
Thermo Fisher Scientific (TMO) has disclosed Common Equity for 16 consecutive years, with $49.0 billion as the latest value for Q3 2024.
- For the quarter ending Q3 2024, Common Equity rose 8.0% year-over-year to $49.0 billion, compared with a TTM value of $49.0 billion through Sep 2024, up 8.0%, and an annual FY2023 reading of $46.7 billion, up 6.11% over the prior year.
- Common Equity was $49.0 billion for Q3 2024 at Thermo Fisher Scientific, up from $47.4 billion in the prior quarter.
- Across five years, Common Equity topped out at $49.0 billion in Q3 2024 and bottomed at $28.6 billion in Q1 2020.
- Average Common Equity over 5 years is $40.4 billion, with a median of $42.3 billion recorded in 2023.
- The sharpest move saw Common Equity grew 3.13% in 2020, then increased 23.52% in 2021.
- Year by year, Common Equity stood at $34.5 billion in 2020, then increased by 18.36% to $40.9 billion in 2021, then rose by 7.78% to $44.0 billion in 2022, then rose by 6.11% to $46.7 billion in 2023, then grew by 4.81% to $49.0 billion in 2024.
- Business Quant data shows Common Equity for TMO at $49.0 billion in Q3 2024, $47.4 billion in Q2 2024, and $45.5 billion in Q1 2024.